Literature DB >> 22472989

Joint modeling of efficacy, dropout, and tolerability in flexible-dose trials: a case study in depression.

A Russu1, E Marostica, G De Nicolao, A C Hooker, I Poggesi, R Gomeni, S Zamuner.   

Abstract

Many difficulties may arise during the modeling of the time course of Hamilton Rating Scale for Depression (HAM D)scores in clinical trials for the evaluation of antidepressant drugs: (i) flexible designs, used to increase the chance of selecting more efficacious doses, (ii) dropout events, and (iii) adverse effects related to the experimental compound.It is crucial to take into account all these factors when designing an appropriate model of the HAM D time course and to obtain a realistic description of the dropout process. In this work, we propose an integrated approach to the modeling of a double-blind, flexible-dose, placebo-controlled, phase II depression trial that comprises response,tolerability, and dropout. We investigate three different dropout mechanisms in terms of informativeness. Goodness of fit is quantitatively assessed with respect to response (HAM D score) and dropout data. We show that dropout is a complex phenomenon that may be influenced by HAM D evolution, dose changes, and occurrence of drug-related adverse effects.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22472989     DOI: 10.1038/clpt.2011.322

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

Review 1.  Disease progression and neuroscience.

Authors:  Nick Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-04-17       Impact factor: 2.745

2.  Population model of longitudinal FEV1 data in asthmatics: meta-analysis and predictability of placebo response.

Authors:  Eleonora Marostica; Alberto Russu; Shuying Yang; Giuseppe De Nicolao; Stefano Zamuner; Misba Beerahee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-08-15       Impact factor: 2.745

3.  Continuous-time Markov modelling of flexible-dose depression trials.

Authors:  Eleonora Marostica; Alberto Russu; Roberto Gomeni; Stefano Zamuner; Giuseppe De Nicolao
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-04       Impact factor: 2.745

4.  Application of Item Response Theory to Model Disease Progression and Agomelatine Effect in Patients with Major Depressive Disorder.

Authors:  Marc Cerou; Sophie Peigné; Emmanuelle Comets; Marylore Chenel
Journal:  AAPS J       Date:  2019-11-12       Impact factor: 4.009

5.  An Innovative Disease-Drug-Trial Framework to Guide Binge Eating Disorder Drug Development: A Case Study for Topiramate.

Authors:  Shamir N Kalaria; Susan L McElroy; Jogarao Gobburu; Mathangi Gopalakrishnan
Journal:  Clin Transl Sci       Date:  2019-09-09       Impact factor: 4.689

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.